On Jul. 29, LNC received the IND approval for the 18F-LNC1001 Injection form the NMPA, and will enter the clinical trial soon.

18F-LNC1001 injection is a PSMA-targeted radionuclide diagnostic drug, registered as Class 1 chemical drugs. Suitable for positron emission tomography (PET) imaging of PSMA- positive prostate cancer patients as follows: patients who are suspected of metastases after initial radical treatment; patients with elevated serum prostate specific antigen (PSA) levels and suspected to have biochemical recurrence. The targeting specificity of PSMA enables the delivery of radionuclide fluorine [18F] to lesion sites of PSMA- positive prostate cancer, by using PET imaging to achieve the diagnostic purpose.

This IND approval is a key step for the LNC’s radiopharmaceuticals innovation platform, and has milestone significance to the research and development of DC PHARM’s nuclear medicine innovation and layout of the entire radiopharmaceutical industry chain.